Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19835882 | 0.83 | MALT1 (0.49) | ADORA1ADORA2APTGS2MALT1DPP4 | |
| SCHEMBL18792160 | 0.82 | DPP4 (0.45) | ADORA1ADORA2ADPP4KMT2A | |
| SCHEMBL20067097 | 0.81 | PDE10A (0.42) | ADORA1DPP4KMT2A | |
| SCHEMBL9695434 | 0.79 | KMT2A (0.66) | ADORA1ADORA2APTGS2DPP4KMT2A | |
| SCHEMBL13342833 | 0.78 | ADORA1 (0.49) | ADORA1ADORA2APTGS2PTGS1MALT1 | |
| SCHEMBL27813726 | 0.76 | IKBKB (0.43) | ADORA1ADORA2ADPP4 | |
| SCHEMBL4582424 | 0.76 | ADORA1 (0.83) | ADORA1ADORA2AGFERKMT2A | |
| Ammonia Solution, Strong SCHEMBL28877790 | 0.74 | ADORA1 (0.81) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL5990731 | 0.73 | ADORA1 (0.54) | ADORA1ADORA2AKMT2A | |
| SCHEMBL1509570 | 0.72 | RAB9A (0.54) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012117216-A1 | N- (ARYLALKYL) - 1H- INDOLE- 2 - SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-09-07 | — | — | WO | disclosed |
| EP-1937672-B1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-7541361-B2 | N-[4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-06-02 | — | — | US | disclosed |
| US-20080176867-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-1937672-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007006928-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176867-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | NQO1, PRMT5, QDPR | ADORA1 73/4885ADORA2A 108/4885PTGS2 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.